FY2010 Extramural NHLBI projects (including all mechanisms) by RCDC topics that transcend disease categories
| RCDC topic . | Nonclinical projects . | Clinical projects . | ||||
|---|---|---|---|---|---|---|
| No. . | Total funding (% extramural funding) . | Median cost per project (25th, 75th percentiles) . | No. . | Total funding (% extramural funding) . | Median cost per project (25th and 75th percentiles) . | |
| All NHLBI | 4279 | 1 402 315 (57%) | 373 (249 410) | 2110 | 1 039 457 (43%) | 375 (138, 620) |
| Aging | 194 | 126 773 (5%) | 384 (328, 471) | 225 | 158 832 (7%) | 441 (234, 738) |
| BBSS | 27 | 10 644 (< 1%) | 347 (137, 394) | 91 | 43 760 (2%) | 370 (140, 636) |
| BSS | 62 | 23 336 (1%) | 333 (180, 394) | 328 | 165 222 (7%) | 430 (146, 724) |
| Bioengineering | 487 | 312 832 (13%) | 374 (212, 568) | 214 | 128 412 (5%) | 393 (197, 661) |
| Biotechnology | 685 | 344 337 (14%) | 379 (249, 449) | 229 | 132 881 (6%) | 399 (135, 719) |
| CER | 2 | 328 (< 1%) | 164 (—) | 88 | 76 779 (3%) | 454 (50, 760) |
| Gene therapy | 83 | 54 126 (2%) | 386 (228, 557) | 22 | 20 779 (1%) | 437 (325, 1868) |
| Genomics | 92 | 85 165 (3%) | 414 (371, 1598) | 134 | 92 047 (4%) | 619 (285, 781) |
| Nanotechnology | 43 | 83 237 (3%) | 393 (212, 707) | 6 | 4314 (< 1%) | 350 (133, 1609) |
| Pediatrics | 263 | 128 799 (5%) | 370 (233, 415) | 320 | 182 147 (7%) | 384 (143, 719) |
| Prevention | 292 | 135 839 (6%) | 369 (229, 419) | 570 | 317 302 (13%) | 436 (149, 733) |
| Stem cells | 411 | 190 552 (8%) | 378 (233, 415) | 140 | 74 160 (3%) | 371 (136, 544) |
| Trials | — | — | — | 444 | 323 579 (13%) | 429 (164, 729) |
| RCDC topic . | Nonclinical projects . | Clinical projects . | ||||
|---|---|---|---|---|---|---|
| No. . | Total funding (% extramural funding) . | Median cost per project (25th, 75th percentiles) . | No. . | Total funding (% extramural funding) . | Median cost per project (25th and 75th percentiles) . | |
| All NHLBI | 4279 | 1 402 315 (57%) | 373 (249 410) | 2110 | 1 039 457 (43%) | 375 (138, 620) |
| Aging | 194 | 126 773 (5%) | 384 (328, 471) | 225 | 158 832 (7%) | 441 (234, 738) |
| BBSS | 27 | 10 644 (< 1%) | 347 (137, 394) | 91 | 43 760 (2%) | 370 (140, 636) |
| BSS | 62 | 23 336 (1%) | 333 (180, 394) | 328 | 165 222 (7%) | 430 (146, 724) |
| Bioengineering | 487 | 312 832 (13%) | 374 (212, 568) | 214 | 128 412 (5%) | 393 (197, 661) |
| Biotechnology | 685 | 344 337 (14%) | 379 (249, 449) | 229 | 132 881 (6%) | 399 (135, 719) |
| CER | 2 | 328 (< 1%) | 164 (—) | 88 | 76 779 (3%) | 454 (50, 760) |
| Gene therapy | 83 | 54 126 (2%) | 386 (228, 557) | 22 | 20 779 (1%) | 437 (325, 1868) |
| Genomics | 92 | 85 165 (3%) | 414 (371, 1598) | 134 | 92 047 (4%) | 619 (285, 781) |
| Nanotechnology | 43 | 83 237 (3%) | 393 (212, 707) | 6 | 4314 (< 1%) | 350 (133, 1609) |
| Pediatrics | 263 | 128 799 (5%) | 370 (233, 415) | 320 | 182 147 (7%) | 384 (143, 719) |
| Prevention | 292 | 135 839 (6%) | 369 (229, 419) | 570 | 317 302 (13%) | 436 (149, 733) |
| Stem cells | 411 | 190 552 (8%) | 378 (233, 415) | 140 | 74 160 (3%) | 371 (136, 544) |
| Trials | — | — | — | 444 | 323 579 (13%) | 429 (164, 729) |
All costs are in units of $1000. All data were obtained from the NIH Research Portfolio Online Reporting Tools (RePORT). Estimates of funding for various RCDCs are at http://report.nih.gov/categorical_spending.aspx. RCDC topics are not necessarily exclusive of one another (hence, total percentages exceed 100). Clinical projects are those categorized in RCDC as “Clinical Research” or “Clinical Trials.” Total NHLBI extramural funding in FY10 was $2 441 772 050. Numbers of projects, total funding in each RCDC area, and median (25th, 75th percentiles) costs per project were calculated using the SAS Version 9.2 “Proc Tabulate” procedure.
BSS indicates behavioral and social sciences; BBSS, basic behavioral and social sciences; CER, comparative effectiveness research; and —, not applicable.